Explore studies of dulaglutide.
Dulaglutide reduced HbA1c 0.24% more than liraglutide in real-world clinical practice (p=0.003), confirmed by meta-analysis of observational studies.
Morieri, Mario Luca; Rigato, Mauro; Frison, Vera; Simioni, Natalino; D'Ambrosio, Michele; Tadiotto, Federica; Paccagnella, Agostino; Lapolla, Annunziata; Avogaro, Angelo; Fadini, Gian Paolo · Observational
Semaglutide subcutaneous was superior to dulaglutide and exenatide ER for HbA1c and weight reduction in head-to-head trials, with both semaglutide and dulaglutide showing cardiovascular and renal benefits.
Patel, Dhiren · Review
GLP-1 RAs (liraglutide, semaglutide, albiglutide, dulaglutide) reduce MACE in T2DM patients with CV disease, while DPP-4 inhibitors show CV safety but no MACE benefit, with saxagliptin increasing HF risk.
Patel, Kershaw V; Sarraju, Ashish; Neeland, Ian J; McGuire, Darren K · Review
GLP-1 RAs increased bone mineral density at multiple skeletal sites over 52 weeks, while placebo showed significant bone loss at the spine, femoral neck, and total hip.
Cai, Ting-Ting; Li, Hui-Qin; Jiang, Lan-Lan; Wang, Hui-Ying; Luo, Meng-Hui; Su, Xiao-Fei; Ma, Jian-Hua · Rct
Semaglutide outperformed dulaglutide in both HbA1c reduction and weight loss, making it the most sought-after GLP-1 drug. Clinicians began prescribing Ozempic (semaglutide for diabetes) off-label for weight loss, even though Wegovy (semaglutide for weight) existed. This drove shortages. Insurance companies responded by requiring prior authorizations proving a type 2 diabetes diagnosis before covering these drugs. The commentary notes that most insurance plans still do not cover GLP-1 drugs solely for weight management, pushing weight-loss demand onto the diabetes supply chain.
Powell, Jason; Taylor, James · Review/Commentary
Among diabetes medications studied for stroke prevention, GLP-1 receptor agonists (specifically semaglutide and dulaglutide) reduced the risk of ischemic stroke in people with type 2 diabetes. Pioglitazone significantly reduced recurrent stroke risk. DPP-4 inhibitors, SGLT2 inhibitors, and insulin did not affect stroke incidence. Metformin monotherapy showed possible stroke reduction but evidence was less definitive.
Prentza, Vasiliki; Pavlidis, George; Ikonomidis, Ignatios; Pililis, Sotirios; Lampsas, Stamatios; Kountouri, Aikaterini; Pliouta, Loukia; Korakas, Emmanouil; Thymis, John; Palaiodimou, Lina; Tsegka, Aikaterini; Markakis, Konstantinos; Halvatsiotis, Panagiotis; Tsivgoulis, Georgios; Lambadiari, Vaia · Systematic Review
After 6 weeks of treatment in rats with metabolic syndrome: - Exenatide improved ejection fraction by 3% vs untreated MetS group - Dulaglutide improved ejection fraction by 7% vs untreated MetS group - Histology showed reduced cardiomyocyte cross-sectional area: 11% reduction with exenatide, 18% with dulaglutide - Both drugs reduced oxidative stress biomarkers - Dulaglutide showed a slight advantage overall
Ravic, Marko; Srejovic, Ivan; Novakovic, Jovana; Andjic, Marijana; Sretenovic, Jasmina; Muric, Maja; Nikolic, Marina; Bolevich, Sergey; Alekseevich Kasabov, Kirill; Petrovich Fisenko, Vladimir; Stojanovic, Aleksandra; Jakovljevic, Vladimir · Animal Study
High-fat diet versus control: liver triglycerides increased 82%, steatosis increased 850%, glucose intolerance increased 71%, insulin increased 98%, and insulin resistance increased 68%. Both drug combinations improved all parameters compared to untreated obese mice: - Empagliflozin + linagliptin: glucose intolerance -60%, insulin -61%, insulin resistance -46%, TAG -61%, steatosis -58% - Empagliflozin + dulaglutide: glucose intolerance -71%, insulin -58%, insulin resistance -62%, TAG -61%, steatosis -82% Principal component analysis clearly separated the groups: the GLP-1 combination was furthest from the disease group, while the DPP-4 combination fell between control and the GLP-1 group.
Reis-Barbosa, Pedro H; Mandarim-de-Lacerda, Carlos A · Animal Study
Analysis of dulaglutide efficacy and safety for weight reduction in diabetic patients confirms meaningful weight loss with acceptable tolerability profile.
Alonazi, Gadah K; Alawuad, Lamia A · Cohort
Descriptive analysis from VigiAccess global pharmacovigilance database characterizes drug-related problems associated with semaglutide across international reporting systems.
Amirthalingam, Palanisamy · Cohort
Analysis of GLP-1 receptor agonist effects on cancer outcomes examines whether these metabolic drugs influence cancer risk, progression, or mortality.
An, Xuedong; Sun, WenJie; Wen, Zhige; Duan, LiYun; Zhang, YueHong; Kang, Xiaomin; Ji, Hangyu; Sun, Yuting; Jiang, Linlin; Zhao, Xuefei; Gao, Qing; Lian, Fengmei · Meta Analysis
Cost-effectiveness analysis shows tirzepatide 5 mg provides superior long-term value compared to dulaglutide through greater metabolic improvements and complication prevention.
Aranishi, Toshihiko; Igarashi, Ataru; Hara, Kazuo; Osumili, Beatrice; Cai, Zhihong; Mizogaki, Aska; Sato, Manaka; Takeuchi, Masakazu; Minghetti, Alice; Hunt, Barnaby; Kadowaki, Takashi · Review
Decreases in leptin and increases in obestatin independently predicted HbA1c reduction with dulaglutide, while changes in BMI or abdominal fat were not associated with glycemic improvement. Responders showed greater beta-cell function improvement and more pronounced food craving reductions.
Jung, Inha; Choi, Hangseok; Choi, In Young; Cho, Hyun Joo; Park, So Young; Lee, Da Young; Seo, Ji A; Kim, Nan Hee; Yu, Ji Hee · Prospective Observational
Tirzepatide at all doses (5, 10, 15 mg) significantly outperformed GLP-1 RAs for both blood sugar control and weight loss when combined with basal insulin.
Osumili, Beatrice; Sapin, Hélène; Yang, Zhengyu; Ranta, Kari; Paik, Jim S; Blüher, Matthias · Meta Analysis
Oral semaglutide reduced HbA1c by 0.85% in naive patients, 0.67% in DPP-4i switchers, and 0.13% in GLP-1 RA switchers.
Oya, Junko; Shimizu, Mika; Kubota, Ryo; Suda, Rika; Nagkagami, Tomoko · Retrospective Cohort